Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Novo Nordisk A/S (NVO) has lowered prices of its blockbuster drug Wegovy for U.S. customers through a new direct-to-consumer online pharmacy, ...

Novo Nordisk (NVO) stock in focus as company launches its direct-to-consumer platform NovoCare Pharmacy for Wegovy delivery.

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

Eli Lilly is growing faster with Zepbound and Mounjaro, as the active ingredient tirzepitide offers a more effective result. Novo Nordisk also cut profits in the second quarter due to weaker ...

New pricing aims to attract cash-paying customers via LillyDirect Hims & Hers warns it may stop selling compounded version of Novo Nordisk ... according to analysts. Eli Lilly began offering ...

Novo Nordisk is doing exceptionally well in the face of the challenges posed by Eli Lilly. So, sales of Ozempic and Wegovy amounted to DKK 53.7 billion in the fourth quarter of 2024, increasing by ...

Novo Nordisk (NYSE: NVO) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly) that's also probably bad news for Hims & Hers Health (NYSE: HIMS).

(Reuters) -Eli Lilly has cut the price for vials of its ... off stiff competition from compounding pharmacies and rival Novo Nordisk. The launch of these vials expands options for patients who ...

Novo Nordisk and Eli Lilly have asked the federal government to list their blockbuster weight-loss drugs on the Pharmaceutical Benefits Scheme, arguing funding the treatment will reduce a costly ...